Kleykamp Bethea A, Ferguson McKenzie C, McNicol Ewan, Bixho Ida, Arnold Lesley M, Edwards Robert R, Fillingim Roger, Grol-Prokopczyk Hanna, Turk Dennis C, Dworkin Robert H
University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Southern Illinois University Edwardsville, School of Pharmacy, Edwardsville, IL, USA.
Semin Arthritis Rheum. 2021 Feb;51(1):166-174. doi: 10.1016/j.semarthrit.2020.10.006. Epub 2020 Dec 29.
Fibromyalgia (FM) is a chronic widespread pain condition that overlaps with multiple comorbid health conditions and contributes to considerable patient distress. The aim of this review was to provide a systematic overview of psychiatric and chronic pain comorbidities among patients diagnosed with FM and to inform the development of recommendations for the design of clinical trials. Thirty-one, cross-sectional, clinical epidemiology studies that evaluated patients diagnosed with FM were included for review. None of the reviewed studies reported on the incidence of these comorbidities. Sample size-weighted prevalence estimates were calculated when prevalence data were reported in 2 or more studies for the same comorbid condition. The most prevalent comorbidity across all studies reviewed was depression/major depressive disorder (MDD) with over half of the patients included having this diagnosis in their lifetime (weighted prevalence up to 63%). In addition, nearly one-third of FM patients examined had current or lifetime bipolar disorder, panic disorder, or post-traumatic stress disorder. Less common psychiatric disorders reported included generalized anxiety disorder, obsessive compulsive disorder, and specific phobias (agoraphobia, social phobia). There were fewer studies that examined chronic pain comorbidities among FM patients, but when evaluated, prevalence was also high ranging from 39% to 76% (i.e., chronic tension-type or migraine headache, irritable bowel syndrome, myofascial pain syndrome, and temporomandibular disorders). The results of the review suggest that depression and chronic pain conditions involving head/jaw pain and IBS were elevated among FM patients compared to other conditions in the clinic-based studies. In contrast, anxiety-related disorders were much less common. Addressing the presence of these comorbid health conditions in clinical trials of treatments for FM would increase the generalizability and real-world applicability of FM research.
纤维肌痛(FM)是一种慢性广泛性疼痛疾病,与多种共病健康状况重叠,给患者带来极大痛苦。本综述的目的是系统概述被诊断为FM的患者中的精神疾病和慢性疼痛共病情况,并为临床试验设计的建议制定提供依据。纳入31项评估被诊断为FM患者的横断面临床流行病学研究进行综述。所综述的研究均未报告这些共病的发病率。当同一共病状况在2项或更多研究中报告患病率数据时,计算样本量加权患病率估计值。在所有综述研究中最常见的共病是抑郁症/重度抑郁症(MDD),超过一半的纳入患者一生中曾有此诊断(加权患病率高达63%)。此外,近三分之一接受检查的FM患者目前或一生中患有双相情感障碍、惊恐障碍或创伤后应激障碍。报告的不太常见的精神疾病包括广泛性焦虑障碍、强迫症和特定恐惧症(广场恐惧症、社交恐惧症)。研究FM患者慢性疼痛共病情况的研究较少,但评估时患病率也很高,范围在39%至76%之间(即慢性紧张型或偏头痛、肠易激综合征、肌筋膜疼痛综合征和颞下颌关节紊乱症)。综述结果表明,在基于临床的研究中,与其他疾病相比,FM患者中抑郁症以及涉及头部/颌部疼痛和肠易激综合征的慢性疼痛状况更为突出。相比之下,焦虑相关障碍则要少见得多。在FM治疗的临床试验中解决这些共病健康状况的问题将提高FM研究的普遍性和实际适用性。